Work

Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.

Year: 2021

Type: article

Abstract: studies in animal models further confirmed that SW620 tumors are the most sensitive tumor to FL118 treatment; SNU-C2B tumors are the second most sensitive tumor to FL118 treatment; and the DLD-1 tumors are the least sensitive tumor. These findings would be useful for predicting FL118 sensitivity to patients' CRC tumors with the defined Kras mutation subtypes under the defined p53/APC genetic status.

Source: PubMed Central

Authors: Rabi Thangaiyan, Ieman Am Aljahdali, Kelsey Y Lent-Moore, Jianqun Liao, Xiang Ling, Fengzhi Li

Institutions: Roswell Park Comprehensive Cancer Center, Canget BioTekpharma (United States)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer, A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer, A novel regimen to target both pancreatic cancer K-ras and antiapoptotic proteins, Roswell Park Cancer Center Support Grant

OpenAlex ID: W3191622767

FWCI: 0.8

Cites: 43

Cited by: 8

Related to: 10